Torsade	torsade	O	DISEASE	OTHERS	I
de	de	O	DISEASE	OTHERS	I
pointes	pointes	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
metoclopramide	metoclopramide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
an	an	O	O	O	O
elderly	elderly	O	O	O	O
woman	woman	O	O	O	O
with	with	O	O	O	O
preexisting	preexisting	O	O	O	O
complete	complete	O	O	O	O
left	left	O	O	OTHERS	I
bundle	bundle	O	O	OTHERS	I
branch	branch	O	O	OTHERS	I
block	block	O	O	OTHERS	I
.	.	O	O	O	O

There	there	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
growing	growing	O	O	O	O
list	list	O	O	O	O
of	of	O	O	O	O
drugs	drugs	O	O	O	O
implicated	implicated	O	O	O	O
in	in	O	O	O	O
acquired	acquired	O	O	O	O
long	long	O	DISEASE	OTHERS	I
QT	qt	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
and	and	O	O	O	O
torsade	torsade	O	DISEASE	OTHERS	I
de	de	O	DISEASE	OTHERS	I
pointes	pointes	O	DISEASE	OTHERS	I
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
torsadogenic	torsadogenic	O	O	O	O
potential	potential	O	O	O	O
of	of	O	O	O	O
metoclopramide	metoclopramide	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
commonly	commonly	O	O	O	O
used	used	O	O	O	O
antiemetic	antiemetic	O	O	O	O
and	and	O	O	O	O
prokinetic	prokinetic	O	O	O	O
drug	drug	O	O	O	O
,	,	O	O	O	O
has	has	O	O	O	O
not	not	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
literature	literature	O	O	O	O
,	,	O	O	O	O
despite	despite	O	O	O	O
its	its	O	O	O	O
chemical	chemical	O	O	O	O
similarity	similarity	O	O	O	O
to	to	O	O	O	O
procainamide	procainamide	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
on	on	O	O	O	O
a	a	O	O	O	O
92-year-old	92-year-old	O	O	O	O
woman	woman	O	O	O	O
with	with	O	O	O	O
preexisting	preexisting	O	O	O	O
complete	complete	O	O	O	O
left	left	O	O	OTHERS	I
bundle	bundle	O	O	OTHERS	I
branch	branch	O	O	OTHERS	I
block	block	O	O	OTHERS	I
who	who	O	O	O	O
developed	developed	O	O	O	O
torsade	torsade	O	DISEASE	OTHERS	I
de	de	O	DISEASE	OTHERS	I
pointes	pointes	O	DISEASE	OTHERS	I
after	after	O	O	O	O
intravenous	intravenous	O	O	O	O
and	and	O	O	O	O
oral	oral	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
metoclopramide	metoclopramide	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

This	this	O	O	O	O
patient	patient	O	O	O	O
also	also	O	O	O	O
developed	developed	O	O	O	O
torsade	torsade	O	DISEASE	OTHERS	I
de	de	O	DISEASE	OTHERS	I
pointes	pointes	O	DISEASE	OTHERS	I
when	when	O	O	O	O
cisapride	cisapride	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
erythromycin	erythromycin	O	O	OTHERS	I
were	were	O	O	O	O
given	given	O	O	O	O
simultaneously	simultaneously	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
two	two	O	O	O	O
episodes	episodes	O	O	O	O
were	were	O	O	O	O
suppressed	suppressed	O	O	O	O
successfully	successfully	O	O	O	O
after	after	O	O	O	O
discontinuing	discontinuing	O	O	O	O
the	the	O	O	O	O
offending	offending	O	O	O	O
drugs	drugs	O	O	O	O
and	and	O	O	O	O
administering	administering	O	O	O	O
class	class	O	O	O	O
IB	ib	O	O	O	O
drugs	drugs	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
is	is	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
documentation	documentation	O	O	O	O
that	that	O	O	O	O
metoclopramide	metoclopramide	CHEMICALS	O	OTHERS	I
provokes	provokes	O	O	O	O
torsade	torsade	O	DISEASE	OTHERS	I
de	de	O	DISEASE	OTHERS	I
pointes	pointes	O	DISEASE	OTHERS	I
clinically	clinically	O	O	O	O
.	.	O	O	O	O

Metoclopramide	metoclopramide	CHEMICALS	O	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
used	used	O	O	O	O
cautiously	cautiously	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
torsade	torsade	O	DISEASE	OTHERS	I
de	de	O	DISEASE	OTHERS	I
pointes	pointes	O	DISEASE	OTHERS	I
.	.	O	O	O	O

